Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target specificity and the cellular target engagement of the...
Saved in:
Main Authors: | Chunlong Ma (Author), Haozhou Tan (Author), Juliana Choza (Author), Yuyin Wang (Author), Jun Wang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In silico phytochemicals analysis as inhibitors of the SARS-COV-2 main protease
by: Ekaterina Serikova, et al.
Published: (2022) -
Chlorhexidine and SARS-CoV-2 main protease: Molecular docking study
by: Vishakha Grover, et al.
Published: (2022) -
QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
by: Fucheng Song, et al.
Published: (2023) -
Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
by: Soumya Gulab Katre, et al.
Published: (2022) -
Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease
by: Denis N. Prada Gori, et al.
Published: (2023)